相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer
Jiefei Han et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
Aude Desnoyer et al.
EUROPEAN JOURNAL OF CANCER (2020)
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Frank B. Cortazar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer
Ganessan Kichenadasse et al.
JAMA ONCOLOGY (2020)
Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge
Sandhya Manohar et al.
KIDNEY360 (2020)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2019)
Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer
Kenneth L. Kehl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi et al.
CLINICAL CANCER RESEARCH (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
Naoya Nishioka et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis
Bi-Cheng Wang et al.
CANCER MEDICINE (2019)
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
David J. Pinato et al.
JAMA ONCOLOGY (2019)
Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
Harish Seethapathy et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
Jian Wang et al.
SCIENTIFIC REPORTS (2019)
Immune dysregulation in cancer patients developing immune-related adverse events
Shaheen Khan et al.
BRITISH JOURNAL OF CANCER (2019)
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Maria Pia Pistillo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
Emma C. de Moel et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
Takayuki Shiroyama et al.
SCIENTIFIC REPORTS (2019)
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
Yoshiyuki Nakamura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab
D. Tomsitz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
Vanessa A. Evans et al.
AIDS (2018)
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
Sander Bins et al.
BRITISH JOURNAL OF CANCER (2018)
HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab
Elaine Chang et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Lorena Ostios-Garcia et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Sara Valpione et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy
Sagun Parakh et al.
ONCOLOGIST (2018)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon et al.
SEMINARS IN CANCER BIOLOGY (2018)
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Taku Fujimura et al.
Oncotarget (2018)
Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
Michael D. Richter et al.
ARTHRITIS & RHEUMATOLOGY (2018)
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer
Yasuo Oshima et al.
JAMA ONCOLOGY (2018)
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
William L. Hwang et al.
JAMA ONCOLOGY (2018)
Treatment-naive HPV plus head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
Steven F. Gameiro et al.
ONCOIMMUNOLOGY (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy
Yeona Cho et al.
FRONTIERS IN ONCOLOGY (2018)
Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy
Neha P. Amin et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
C. Rudin et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma
Alexander C. Hopkins et al.
JCI INSIGHT (2018)
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer
A. Guihot et al.
ANNALS OF ONCOLOGY (2018)
High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy
M. Kotake et al.
ANNALS OF ONCOLOGY (2017)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
David Y. Oh et al.
CANCER RESEARCH (2017)
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota
Jonathan M. Pitt et al.
ONCOIMMUNOLOGY (2017)
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Ralf Gutzmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid
Taku Fujimura et al.
EXPERIMENTAL DERMATOLOGY (2017)
Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes
Thomas Clavel et al.
IMMUNOLOGICAL REVIEWS (2017)
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
Andrew Bang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
Yasuhiro Fujisawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
Ryota Tanaka et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Inflammation and sarcopenia: A systematic review and meta-analysis
Giulia Bano et al.
MATURITAS (2017)
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
Amelie Aboudaram et al.
MELANOMA RESEARCH (2017)
Neutrophils in cancer: prognostic role and therapeutic strategies
Alberto Ocana et al.
MOLECULAR CANCER (2017)
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Shigeaki Suzuki et al.
NEUROLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
Adam Diehl et al.
ONCOTARGET (2017)
Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer
Brennan McCullar et al.
JOURNAL OF THORACIC DISEASE (2017)
Eosinophils in Autoimmune Diseases
Nicola L. Diny et al.
FRONTIERS IN IMMUNOLOGY (2017)
Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer Results From the C SCANS Study
Elizabeth M. Cespedes Feliciano et al.
JAMA ONCOLOGY (2017)
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients
M. V. Heppt et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab in HIV-related non-small-cell lung cancer
M. Hentrich et al.
ANNALS OF ONCOLOGY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
Elizabeth H. Byrne et al.
CANCER (2017)
Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab
Gwenaelle Le Garff et al.
AIDS (2017)
Mechanisms of Drug-Induced Interstitial Nephritis
Rajeev Raghavan et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2017)
The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
Louise E. Daly et al.
BRITISH JOURNAL OF CANCER (2017)
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Anushree C. Shirali et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab
Rosie Qin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases
Mubeccel Akdis et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K. Subudhi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
Xiao Xiao et al.
CANCER DISCOVERY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).
Alexander M. Menzies et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
Naoka Murakami et al.
CLINICAL KIDNEY JOURNAL (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis
Anthony P. Heaney et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genetics of autoimmune diseases: insights from population genetics
Paula S. Ramos et al.
JOURNAL OF HUMAN GENETICS (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R. Minor et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4
Sebastian Zeissig et al.
GUT (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
High CTLA-4 Expression on Th17 Cells Results in Increased Sensitivity to CTLA-4 Coinhibition and Resistance to Belatacept
S. M. Krummey et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Plasmacytoid Dendritic Cells Mediate Anti-inflammatory Responses to a Gut Commensal Molecule via Both Innate and Adaptive Mechanisms
Suryasarathi Dasgupta et al.
CELL HOST & MICROBE (2014)
Eosinophilic Replacement Infiltrates in Cystic Hashimoto's Thyroiditis: a Potential Diagnostic Pitfall
Kim R. Geisinger et al.
ENDOCRINE PATHOLOGY (2014)
Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis
Morten Stilund et al.
PLOS ONE (2014)
Epstein-Barr Virus and Human Papillomavirus Infections and Genotype Distribution in Head and Neck Cancers
Zeyi Deng et al.
PLOS ONE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma
Maria Li Lung et al.
CHINESE JOURNAL OF CANCER (2014)
CD163 and Inflammation: Biological, Diagnostic, and Therapeutic Aspects
Anders Etzerodt et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
O. Huillard et al.
BRITISH JOURNAL OF CANCER (2013)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
PD-1 is a novel regulator of human B-cell activation
Marie-Laure Thibult et al.
INTERNATIONAL IMMUNOLOGY (2013)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The influence of sex and gender on the immune response
Sabine Oertelt-Prigione
AUTOIMMUNITY REVIEWS (2012)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
Serena S. Kwek et al.
JOURNAL OF IMMUNOLOGY (2012)
Cytokine Gene Polymorphisms and Human Autoimmune Disease in the Era of Genome-Wide Association Studies
Koen Vandenbroeck
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
Shimpei Kawamoto et al.
SCIENCE (2012)
Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma
Michael S. Sabel et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs, and Skin
Casey T. Weaver et al.
Annual Review of Pathology-Mechanisms of Disease (2011)
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Veronique Corbiere et al.
CANCER RESEARCH (2011)
Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
Matthew M. Burke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Koji Atarashi et al.
SCIENCE (2011)
Sex differences in autoimmune diseases
Rhonda Voskuhl
Biology of Sex Differences (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Biology of interleukin-10
Robert Sabat et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Identification of PD-1 as a Unique Marker for Failing Immune Reconstitution in HIV-1–Infected Patients on Treatment
Katharina Grabmeier-Pfistershammer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Defining and analyzing geoepidemiology and human autoimmunity
Yinon Shapira et al.
JOURNAL OF AUTOIMMUNITY (2010)
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis
Monika Müller et al.
LANCET INFECTIOUS DISEASES (2010)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
Carla M. M. Prado et al.
CLINICAL CANCER RESEARCH (2009)
PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention
Daniel E. Kaufmann et al.
JOURNAL OF IMMUNOLOGY (2009)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Vijayakumar Velu et al.
NATURE (2009)
Human Regulatory T Cell Suppressive Function Is Independent of Apoptosis Induction in Activated Effector T Cells
Yvonne Vercoulen et al.
PLOS ONE (2009)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
Induction of IL-17+ T cell trafficking and development by IFN-γ:: Mechanism and pathological relevance in psoriasis
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2008)
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
Harry Sokol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma
JM Reuben et al.
CANCER (2006)
An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system
SK Mazmanian et al.
CELL (2005)
PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis
HL Ding et al.
CLINICAL IMMUNOLOGY (2005)
Suppressed T-cell activation by IFN-γ-induced expression of PD-L1 on renal tubular epithelial cells
R Schoop et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope
L Prokunina et al.
ARTHRITIS AND RHEUMATISM (2004)
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells
C Blank et al.
JOURNAL OF IMMUNOLOGY (2003)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda et al.
NATURE (2003)
Increased serum concentration of eosinophil-derived neurotoxin in patients with Graves' disease
Y Hidaka et al.
THYROID (2003)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3
N Matsushita et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
B cells regulate autoimmunity by provision of IL-10
S Fillatreau et al.
NATURE IMMUNOLOGY (2002)
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
C Lock et al.
NATURE MEDICINE (2002)
Epitope spreading in immunemediated diseases: Implications for immunotherapy
CL Vanderlugt et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation
A Mizoguchi et al.
IMMUNITY (2002)
Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction
E Lubberts et al.
INFLAMMATION RESEARCH (2002)
Chemokines and the tissue-specific migration of lymphocytes
EJ Kunkel et al.
IMMUNITY (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression
BM Carreno et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
